ARTV advances pivotal Phase III trial in refractory RA
A novel NK cell platform is advancing in autoimmune disease with a pivotal Phase III trial in refractory RA targeting deep B-cell depletion, citing promising early efficacy and safety.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
ARTV advances pivotal Phase III trial for refractory RA
ARTV’s AlloNK cell platform is advancing in a pivotal Phase III trial for refractory RA. Enrollment is robust, with data updates expected by year-end and top-line results targeted for 2028.